Drug Profile


Alternative Names: PLX R 18; PLX RAD

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Hadassah Medical School; Pluristem Therapeutics
  • Developer Case Western Reserve University; Hadassah Medical School; National Institute of Allergy and Infectious Diseases; Pluristem Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Bone marrow cell stimulants; Cell differentiation modulators; Cell replacements; Granulocyte colony stimulating factor stimulants; Interleukin-6 modulators; Stem cell modulators; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aplastic anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Aplastic anaemia
  • Preclinical Acute radiation syndrome; Graft-versus-host disease

Most Recent Events

  • 07 Nov 2016 Pluristem Therapeutics receives patent allowance for adherent cells from adipose or placental tissues and their therapeutics use in China
  • 13 May 2016 Pluristem announces intention to submit BLA to US FDA under the Animal Rule regulatory pathway for Acute radiation syndrome
  • 10 May 2016 Pluristem plans to seek Fast track designation with the US FDA for PLX R18 for Graft versus host disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top